Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evolocumab in patients with homozygous familial hypercholesterolemia in India.

Journal of clinical lipidology - 1 Jan 2000

Bansal Sandeep, Ruzza Andrea, Sawhney Jps, Kulkarni Govind, Iyengar Shammana, Mehta Vimal, Hamer Andrew, Wu You, Raal Frederick J

Abstract excerpt

BACKGROUND: Evolocumab is a fully human monoclonal antibody inhibitor of proprotein convertase subtilisin/kexin type 9 approved in India for treatment of homozygous familial hypercholesterolemia (HoFH) in patients aged ≥12 years. OBJECTIVE: RAMAN (NCT03403374) was a single-country, open-label, phase 4 study evaluating the safety and tolerability of evolocumab in patients with HoFH in India. METHODS: Patients ≥12...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Apolipoproteins B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Arthralgia

Share to Cholesterol, LDL

Share to Lipoprotein(a)

Share to Outcome Assessment, Health Care

Share to Receptors, LDL

Share to Skin Diseases

Source

Identifiers

PMID: 34750081
DOI: 10.1016/j.jacl.2021.10.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolocumab in patients with homozygous familial hypercholesterolemia in India.PMID 34750081Read ↗

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.Semantic proximity Read ↗

Evolocumab in Pediatric Heterozygous Familial HypercholesterolemiaSemantic proximity Read ↗

Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.Semantic proximity Read ↗

Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.Semantic proximity Read ↗

Efficacy and Safety of Alirocumab in Patients With Autosomal Dominant Hypercholesterolemia Associated With Proprotein Convertase Subtilisin/Kexin Type 9 Gain-of-Function or Apolipoprotein B Loss-of-Function Mutations.Semantic proximity Read ↗

Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India.Semantic proximity Read ↗

Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.Semantic proximity Read ↗

Homozygous familial hypercholesterolemia (HoFH) in Canada.Semantic proximity Read ↗

Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody.Semantic proximity Read ↗

Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies.Semantic proximity Read ↗

PCSK9: From discovery to therapeutic applications.Semantic proximity Read ↗

Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.